Overview

Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury

Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The SyNAPSe trial will study if giving intravenous (i.v.) progesterone within 8 hours of the injury for a total of 120 hours to severe traumatic brain injury patients improves their recovery.
Phase:
Phase 3
Details
Lead Sponsor:
BHR Pharma, LLC
Collaborators:
INC Research
PRA Health Sciences
Syneos Health
Treatments:
Progesterone